TRPV1 in experimental autoimmune prostatitis.
Animals
Arginine
/ analogs & derivatives
Autoimmune Diseases
/ drug therapy
Extracellular Signal-Regulated MAP Kinases
/ metabolism
Ganglia, Spinal
/ metabolism
Hyperalgesia
/ drug therapy
Male
Mast Cells
/ immunology
Mice
Mice, Inbred C57BL
Mice, Knockout
Oligopeptides
/ pharmacology
Pelvic Pain
/ drug therapy
Phosphorylation
Prostatitis
/ drug therapy
Spinal Cord
/ metabolism
TRPV Cation Channels
/ antagonists & inhibitors
CPPS
inflammation
mast cells
pelvic pain
vanilloid 1
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
05
09
2018
accepted:
18
09
2019
pubmed:
2
10
2019
medline:
14
4
2020
entrez:
2
10
2019
Statut:
ppublish
Résumé
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a disorder that is characterized by persistent pelvic pain in men of any age. Although several studies suggest that the transient receptor potential vanilloid 1 (TRPV1) channel is involved in various pathways of chronic pain, the TRPV1 channel has not been implicated in chronic pelvic pain associated with CP/CPPS. Male C57BL/6J (B6) and TRPV1 knockout (TRPV1 KO) mice (5-7 weeks old) were used to study the development of pelvic allodynia in a murine model of CP/CPPS called experimental autoimmune prostatitis (EAP). The prostate lobes, dorsal root ganglia (DRG), and spinal cord were excised at day 20. The prostate lobes were assessed for inflammation, TRPV1 expression, and mast cell activity. DRG and spinal cord, between the L6-S4 regions, were analyzed to determine the levels of phosphorylated ERK1/2 (p-ERK 1/2). To examine the therapeutic potential of TRPV1, B6 mice with EAP received intraurethral infusion of a TRPV1 antagonist at day 20 (repeated every 2 days) and pelvic pain was evaluated at days 20, 25, 30, and 35. Our data showed that B6 mice with EAP developed pelvic tactile allodynia at days 7, 14, and 20. In contrast, TRPV1 KO mice with EAP do not develop pelvic tactile allodynia at any time point. Although we observed no change in the levels of TRPV1 protein expression in the prostate from B6 mice with EAP, there was evidence of significant inflammation and elevated mast cell activation. Interestingly, the prostate from TRPV1 KO mice with EAP showed a lack of mast cell activation despite evidence of prostate inflammation. Next, we observed a significant increase of p-ERK1/2 in the DRG and spinal cord from B6 mice with EAP; however, p-ERK1/2 expression was unaltered in TRPV1 KO mice with EAP. Finally, we confirmed that intraurethral administration of a TRPV1 antagonist peptide reduced pelvic tactile allodynia in B6 mice with EAP after day 20. We demonstrated that in a murine model of CP/CPPS, the TRPV1 channel is key to persistent pelvic tactile allodynia and blocking TRPV1 in the prostate may be a promising strategy to quell chronic pelvic pain.
Sections du résumé
BACKGROUND
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a disorder that is characterized by persistent pelvic pain in men of any age. Although several studies suggest that the transient receptor potential vanilloid 1 (TRPV1) channel is involved in various pathways of chronic pain, the TRPV1 channel has not been implicated in chronic pelvic pain associated with CP/CPPS.
METHODS
Male C57BL/6J (B6) and TRPV1 knockout (TRPV1 KO) mice (5-7 weeks old) were used to study the development of pelvic allodynia in a murine model of CP/CPPS called experimental autoimmune prostatitis (EAP). The prostate lobes, dorsal root ganglia (DRG), and spinal cord were excised at day 20. The prostate lobes were assessed for inflammation, TRPV1 expression, and mast cell activity. DRG and spinal cord, between the L6-S4 regions, were analyzed to determine the levels of phosphorylated ERK1/2 (p-ERK 1/2). To examine the therapeutic potential of TRPV1, B6 mice with EAP received intraurethral infusion of a TRPV1 antagonist at day 20 (repeated every 2 days) and pelvic pain was evaluated at days 20, 25, 30, and 35.
RESULTS
Our data showed that B6 mice with EAP developed pelvic tactile allodynia at days 7, 14, and 20. In contrast, TRPV1 KO mice with EAP do not develop pelvic tactile allodynia at any time point. Although we observed no change in the levels of TRPV1 protein expression in the prostate from B6 mice with EAP, there was evidence of significant inflammation and elevated mast cell activation. Interestingly, the prostate from TRPV1 KO mice with EAP showed a lack of mast cell activation despite evidence of prostate inflammation. Next, we observed a significant increase of p-ERK1/2 in the DRG and spinal cord from B6 mice with EAP; however, p-ERK1/2 expression was unaltered in TRPV1 KO mice with EAP. Finally, we confirmed that intraurethral administration of a TRPV1 antagonist peptide reduced pelvic tactile allodynia in B6 mice with EAP after day 20.
CONCLUSIONS
We demonstrated that in a murine model of CP/CPPS, the TRPV1 channel is key to persistent pelvic tactile allodynia and blocking TRPV1 in the prostate may be a promising strategy to quell chronic pelvic pain.
Identifiants
pubmed: 31573117
doi: 10.1002/pros.23913
pmc: PMC7313375
mid: NIHMS1601066
doi:
Substances chimiques
Oligopeptides
0
TRPV Cation Channels
0
TRPV1 protein, mouse
0
Arginine
94ZLA3W45F
Extracellular Signal-Regulated MAP Kinases
EC 2.7.11.24
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
28-37Subventions
Organisme : NIDDK NIH HHS
ID : F32 DK104544
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK083609
Pays : United States
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
J Vis Exp. 2013 Jan 16;(71):e50158
pubmed: 23353558
J Urol. 2005 May;173(5):1590-4
pubmed: 15821499
J Mol Neurosci. 2010 Sep;42(1):80-8
pubmed: 20411352
World J Urol. 2013 Aug;31(4):733-9
pubmed: 23568443
Eur J Pain. 2019 Nov;23(10):1767-1779
pubmed: 31314954
Eur Respir J. 2016 Aug;48(2):380-92
pubmed: 27126687
Biochim Biophys Acta. 2016 Aug;1863(8):2054-64
pubmed: 27180305
J Immunol. 2012 Jun 1;188(11):5741-51
pubmed: 22547700
Prostate. 2017 Jan;77(1):94-104
pubmed: 27699823
Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):11342-11347
pubmed: 27638213
Mol Cell Neurosci. 2007 Nov;36(3):381-91
pubmed: 17851089
Osteoarthritis Cartilage. 2009 Feb;17(2):244-51
pubmed: 18684647
BJU Int. 2001 Jun;87(9):797-805
pubmed: 11412216
J Urol. 2012 Apr;187(4):1473-82
pubmed: 22341813
Prostate Cancer Prostatic Dis. 2007;10(1):15-29
pubmed: 17199136
Arthritis Rheum. 2005 Oct;52(10):3248-56
pubmed: 16200599
Pain. 2014 Jul;155(7):1328-38
pubmed: 24726923
Int Arch Allergy Immunol. 2011;156(3):305-12
pubmed: 21720176
Am J Gastroenterol. 2014 Jan;109(1):99-109
pubmed: 24189713
Oncotarget. 2016 Jan 5;7(1):148-60
pubmed: 26700618
Eur J Pain. 2018 Aug;22(7):1214-1228
pubmed: 29504187
Mediators Inflamm. 2017;2017:2786427
pubmed: 28831207
J Neurosci. 2013 Mar 27;33(13):5603-11
pubmed: 23536075
Subst Abus. 2018;39(4):441-448
pubmed: 29595408
Allergy Asthma Immunol Res. 2018 May;10(3):216-224
pubmed: 29676068
J Neurosci. 2007 Jan 24;27(4):832-9
pubmed: 17251423
Pharmaceuticals (Basel). 2012 Aug 17;5(8):837-52
pubmed: 24280677
Pancreas. 2008 May;36(4):394-401
pubmed: 18437086
Nature. 2000 May 11;405(6783):183-7
pubmed: 10821274
Curr Pain Headache Rep. 2018 Feb 23;22(3):16
pubmed: 29476358
J Urol. 2008 Oct;180(4):1378-82
pubmed: 18707716
Neuron. 1998 Sep;21(3):531-43
pubmed: 9768840
Urology. 2002 Dec;60(6 Suppl):1-4
pubmed: 12521576
J Dermatol Sci. 2018 Dec;92(3):264-271
pubmed: 30527377
PLoS One. 2017 Feb 3;12(2):e0171366
pubmed: 28158279
Nature. 1997 Oct 23;389(6653):816-24
pubmed: 9349813
Am J Physiol Regul Integr Comp Physiol. 2008 Apr;294(4):R1268-75
pubmed: 18287220
Prostate. 2015 Jan;75(1):50-9
pubmed: 25263093
Pharmacol Res. 2018 May;131:231-243
pubmed: 29438782
Eur Urol. 2004 Dec;46(6):792-8
pubmed: 15548449
Am J Physiol Gastrointest Liver Physiol. 2015 Jul 15;309(2):G87-99
pubmed: 26021808
Exp Dermatol. 2004 Mar;13(3):129-39
pubmed: 14987252
Sci Rep. 2017 Mar 13;7:44322
pubmed: 28287157
Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9099-104
pubmed: 19458046
J Immunol. 1995 Jul 1;155(1):297-307
pubmed: 7602107
Clin Vaccine Immunol. 2013 Jul;20(7):1008-15
pubmed: 23637043
Pain. 2018 Oct;159(10):2105-2114
pubmed: 30015705
Pathol Res Pract. 1993 Mar;189(2):156-62
pubmed: 8321743
Biomed Res Int. 2017;2017:5068347
pubmed: 29379798
Scand J Pain. 2017 Oct;17:134-143
pubmed: 28850367
J Neuroinflammation. 2013 Jan 11;10:3
pubmed: 23305398
J Autoimmun. 2009 Mar;32(2):140-8
pubmed: 19269787
Science. 2000 Apr 14;288(5464):306-13
pubmed: 10764638
Biomed Pharmacother. 2018 Mar;99:261-270
pubmed: 29334670
Neuroscience. 2011 Oct 13;193:440-51
pubmed: 21763756
PLoS One. 2015 May 01;10(5):e0125623
pubmed: 25933188
J Biol Chem. 2016 Jan 8;291(2):640-51
pubmed: 26515068
Nat Immunol. 2016 Jul;17(7):878-87
pubmed: 27135604
Eur J Pharmacol. 2018 Jun 5;828:42-51
pubmed: 29577893
J Pharmacol Sci. 2017 Apr;133(4):254-260
pubmed: 28410966
Biol Pharm Bull. 2011;34(7):1105-8
pubmed: 21720020
Neuropharmacology. 2016 Feb;101:330-40
pubmed: 26453963
J Bone Miner Metab. 2018 May;36(3):274-285
pubmed: 28516219
Acta Physiol (Oxf). 2018 Jul;223(3):e13088
pubmed: 29729213